Related Experiment Video
Updated: Aug 19, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.3K
Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability
Yi-Hsuan Lin1, Chia-Hung Lin2,3, Yu-Yao Huang2,4
1Department of Biological Science and Techonology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
European Journal of Medical Research
|December 3, 2022
Summary
Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) plus basal insulin stabilize glycemic variability (GV) better than pre-mixed insulin. GLP-1 RA diminishes the impact of food components on GV, especially during daytime.
Area of Science:
- Endocrinology
- Metabolism
- Diabetes Management
Background:
- Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) show potential in stabilizing glycemic variability (GV) and influencing eating behaviors.
- Continuous glucose monitoring (CGM) is a key tool for assessing GV in diabetes management.
Purpose of the Study:
- To compare the effects of insulin, GLP-1 RA, and dietary components on GV.
- To evaluate the impact of switching from pre-mixed insulin to a GLP-1 RA regimen on GV in type 2 diabetes patients.
Main Methods:
- Patients with type 2 diabetes underwent CGM before and after regimen change.
- Dietary intake was analyzed by a certified dietitian.
- Interactions between medical regimen, GV indices (MAGE, SD, CV), and nutrient components were analyzed.
Main Results:
- No significant differences in diet or calorie intake were observed between the pre-mixed insulin and GLP-1 RA regimens.
- GLP-1 RA regimen showed reduced MAGE and SD with increased fat intake, and decreased CV with increased protein intake.
- The impact of food intake on GV indices was diminished with the GLP-1 RA regimen, leading to significantly lower MAGE, SD, and CV values.
Conclusions:
- A GLP-1 RA plus basal insulin regimen offers superior GV stabilization compared to twice-daily pre-mixed insulin.
- GLP-1 RA therapy can attenuate the influence of dietary components on glycemic control.
- The benefits of GLP-1 RA on GV are particularly notable during daytime hours.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
383
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
383
01:06Oral Hypoglycemic Agents: Glinides
211
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
211
01:23Dipeptidyl Peptidase 4 Inhibitors
230
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
230
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
259
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
259
01:16Insulin: Dosing Regimen and Adverse Effects
226
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
226
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
234
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
234